A study found that Quest Diagnostics’ Haystack MRD ctDNA test detected colorectal cancer recurrence with up to 100% specificity, outperforming CEA testing in DYNAMIC trial patient specimens.
The study demonstrated that patients who test positive for ctDNA "actually benefit from chemotherapy."
Irish researchers have secured €670,000 to clinically validate a blood-based colorectal cancer screening test using inflammatory biomarkers, aiming for launch by 2027 through a new spin-out company.
A multicenter study reports that combining fecal SDC2 methylation testing with the APCS scoring system improves advanced adenoma detection and specificity in colorectal cancer screening.
Read More
Guardant Health will provide up to 100 free Shield blood tests per organization to support colorectal cancer screening events and outreach during Colorectal Cancer Awareness Month in March.
Read More
The FDA has approved a companion diagnostic for identifying BRAF V600E-mutant metastatic colorectal cancer patients eligible for encorafenib combination therapy.
Read More
CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testing.
Read More
The collaboration will combine New Day’s liquid biopsy technology with Daisy Genomics’ physics-based sequencing platform to advance early CRC screening.
Read More
The biotechnology company’s integrated screening approach combines whole-genome sequencing, imaging, and multiple biomarker tests to enable early detection.
Read More
Circulating tumor DNA testing can identify stage 3 patients who may safely receive reduced treatment intensity, international study finds.
Read More
The company is collaborating with Guardant Health to make Guardant’s Shield test available through Quest’s nationwide network of provider clients and patient service centers.
Read More
The test provides fully automated, sample-to-result testing to identify patients eligible for immunotherapy treatment.
Read More
Personalis has expanded and extended its partnership with Tempus AI to include colorectal cancer in their NeXT Personal MRD test.
Read More
Vibrant Wellness has enhanced its Gut Zoomer microbiome panel with expanded microbial and metabolite testing.
Read More
A study found that colorectal cancer screening could be boosted by using a rapid, accurate app-read smartphone FIT.
Read More
New Day Diagnostics has launched ColoHealth, a physician-mediated blood test for colorectal cancer screening.
Read More
Natural disasters and the COVID-19 pandemic disrupted colorectal cancer diagnoses in Puerto Rico, leading to a rise in delayed diagnoses.
Read More
Sysmex America will distribute Sentinel Diagnostics SENTiFIT 270 and 800 analyzers in Canada for colorectal cancer (CRC) screening.
Read More